Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GERMAN HERNANDEZ

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1154367704
CMS profile
323879
Location
EL PASO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$297,348.23

479 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 10 of 10; records 451–479 of 479 matching records. This page contains 29 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GERMAN HERNANDEZ

NPI 1154367704 · CMS profile ID 323879

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

EL PASO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 10 of 10; records 451–479 of 479 matching records. This page contains 29 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1154367704?year=2023&recipient=provider&page=10#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GERMAN HERNANDEZ, NPI 1154367704, CMS profile ID 323879. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 10 of 10; records 451–479 of 479 matching records. This page contains 29 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1154367704?year=2023&recipient=provider&page=10#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). GERMAN HERNANDEZ, NPI 1154367704, CMS profile ID 323879. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 10 of 10; records 451–479 of 479 matching records. This page contains 29 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1154367704?year=2023&recipient=provider&page=10#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
GERMAN HERNANDEZ, NPI 1154367704, CMS profile ID 323879, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 10 of 10; records 451–479 of 479 matching records. This page contains 29 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1154367704?year=2023&recipient=provider&page=10#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

479 matching records · $297,348.23 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 479 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 451–479 of 479.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Aurinia Pharma U.S., Inc. $900.0001/17/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057735143 CMS
Alexion Pharmaceuticals, Inc. $14.7601/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017045273 CMS
Bayer Healthcare Pharmaceuticals Inc. $6.2601/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000547644 CMS
Bayer Healthcare Pharmaceuticals Inc. $597.8101/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000661087 CMS
AstraZeneca Pharmaceuticals LP $18.7801/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016177415 CMS
Otsuka America Pharmaceutical, Inc. $1,435.0001/10/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014399483 CMS
Vifor Pharma, Inc. $7.8101/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1013094255 CMS
GlaxoSmithKline, LLC. $24.7501/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002596107 CMS
Aurinia Pharma U.S., Inc. $56.0601/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057735131 CMS
Aurinia Pharma U.S., Inc. $56.0601/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057735133 CMS
Aurinia Pharma U.S., Inc. $56.0601/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057735135 CMS
Aurinia Pharma U.S., Inc. $56.0601/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057735137 CMS
Aurinia Pharma U.S., Inc. $56.0601/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057735139 CMS
Aurinia Pharma U.S., Inc. $56.0801/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057735141 CMS
Dexcom, Inc. $15.0401/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1054614523 CMS
Aurinia Pharma U.S., Inc. $52.8301/04/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057735105 CMS
Aurinia Pharma U.S., Inc. $24.0001/04/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057735107 CMS
Aurinia Pharma U.S., Inc. $52.8301/04/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057735109 CMS
Aurinia Pharma U.S., Inc. $24.0001/04/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057735111 CMS
Aurinia Pharma U.S., Inc. $52.8301/04/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057735113 CMS
Aurinia Pharma U.S., Inc. $24.0001/04/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057735115 CMS
Aurinia Pharma U.S., Inc. $52.8301/04/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057735117 CMS
Aurinia Pharma U.S., Inc. $23.9801/04/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057735119 CMS
Aurinia Pharma U.S., Inc. $52.8301/04/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057735121 CMS
Aurinia Pharma U.S., Inc. $24.0001/04/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057735125 CMS
Aurinia Pharma U.S., Inc. $52.8501/04/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057735127 CMS
Aurinia Pharma U.S., Inc. $24.0001/04/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057735129 CMS
AstraZeneca Pharmaceuticals LP $151.5201/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011772649 CMS
Vifor Pharma, Inc. $6.7701/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1013092633 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $155,503.13 300
PY2020 $31,104.08 87
PY2021 $193,078.64 297
PY2022 $260,191.91 441
PY2023 $297,348.23 479
PY2024 $250,158.80 460
PY2025 $125,000.62 284

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,544,540.09 215
PY2024 Principal investigator $1,163,821.68 76
PY2023 Principal investigator $1,080,573.81 96
PY2022 Principal investigator $1,022,991.67 77
PY2021 Principal investigator $1,367,175.73 134
PY2020 Principal investigator $574,586.11 215
PY2019 Principal investigator $584,254.36 531

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

215 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 CSL Behring $3,302.00 12/29/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678258
Principal investigator 1 GENZYME CORPORATION $1,385.00 12/08/2025 Non-covered Recipient Entity
Total Renal Research Inc Davita Clinical Research
ACT - POC clinical study - CD40L mAb - frexalimab No dispute reported 06/30/2026 1226083935
Principal investigator 1 CSL Behring $75.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678596
Principal investigator 1 CSL Behring $204.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678598
Principal investigator 1 CSL Behring $204.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678600
Principal investigator 1 CSL Behring $204.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678602
Principal investigator 1 CSL Behring $300.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678604
Principal investigator 1 CSL Behring $338.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678606
Principal investigator 1 CSL Behring $1,352.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678692
Principal investigator 1 AKEBIA THERAPEUTICS INC $216.00 12/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841609
Principal investigator 1 AKEBIA THERAPEUTICS INC $216.00 12/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841613
Principal investigator 1 Alnylam Pharmaceuticals Inc. $780.00 12/01/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522128
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,750.00 12/01/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522130
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,230.00 12/01/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522132
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,714.00 12/01/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522134
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,840.00 12/01/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522136
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,448.00 12/01/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522138
Principal investigator 1 Alnylam Pharmaceuticals Inc. $720.00 12/01/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522140
Principal investigator 1 Alnylam Pharmaceuticals Inc. $720.00 12/01/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522142
Principal investigator 1 Alnylam Pharmaceuticals Inc. $860.00 12/01/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522144
Principal investigator 1 Alnylam Pharmaceuticals Inc. $120.00 12/01/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522146
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,300.00 12/01/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522148
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6,014.00 12/01/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522150
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,300.00 12/01/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522298
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,040.00 12/01/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522300
Principal investigator 1 Alnylam Pharmaceuticals Inc. $720.00 12/01/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522302
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,040.00 12/01/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522304
Principal investigator 1 CSL Behring $60.54 11/26/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678032
Principal investigator 1 Novartis Pharmaceuticals Corporation $84,294.20 11/19/2025 Non-covered Recipient Entity
EL PASO KIDNEY SPECIALISTS
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults With IgA Nephropathy (The BEYOND Study) No dispute reported 06/30/2026 1190312923
Principal investigator 1 CSL Behring $9,729.00 11/17/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678944
Principal investigator 1 GENZYME CORPORATION $1,222.00 11/17/2025 Non-covered Recipient Entity
Total Renal Research Inc Davita Clinical Research
ACT - POC clinical study - CD40L mAb - frexalimab No dispute reported 06/30/2026 1226083910
Principal investigator 1 Calliditas Therapeutics US Inc. $650.00 11/10/2025 Non-covered Recipient Entity
MEDRESEARCH INC
Nef-403 No dispute reported 06/30/2026 1235023514
Principal investigator 1 AKEBIA THERAPEUTICS INC $764.00 11/05/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841539
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 11/05/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841541
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 11/05/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841543
Principal investigator 1 AKEBIA THERAPEUTICS INC $764.00 11/05/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841545
Principal investigator 1 AKEBIA THERAPEUTICS INC $801.00 11/05/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841607
Principal investigator 1 AKEBIA THERAPEUTICS INC $917.00 11/05/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841611
Principal investigator 1 AKEBIA THERAPEUTICS INC $213.00 11/05/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842682
Principal investigator 1 AKEBIA THERAPEUTICS INC $213.00 11/05/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842808
Principal investigator 1 AKEBIA THERAPEUTICS INC $265.00 11/05/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842810
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 11/05/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842830
Principal investigator 1 AKEBIA THERAPEUTICS INC $729.00 11/05/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842844
Principal investigator 1 AKEBIA THERAPEUTICS INC $84.00 11/05/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843078
Principal investigator 1 AKEBIA THERAPEUTICS INC $354.00 11/05/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843080
Principal investigator 1 AKEBIA THERAPEUTICS INC $84.00 11/05/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843082
Principal investigator 1 AKEBIA THERAPEUTICS INC $354.00 11/05/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843084
Principal investigator 1 AKEBIA THERAPEUTICS INC $53.00 11/05/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843222
Principal investigator 1 AKEBIA THERAPEUTICS INC $222.00 11/05/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843224
Principal investigator 1 AKEBIA THERAPEUTICS INC $30.00 11/05/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843226
Principal investigator 1 AKEBIA THERAPEUTICS INC $126.00 11/05/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843228
Principal investigator 1 GENZYME CORPORATION $2,800.00 11/04/2025 Non-covered Recipient Entity
Total Renal Research Inc Davita Clinical Research
ACT - POC clinical study - CD40L mAb - frexalimab No dispute reported 06/30/2026 1226083901
Principal investigator 1 CSL Behring $2,024.61 10/31/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678022
Principal investigator 1 CSL Behring $32,852.00 10/29/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678922
Principal investigator 1 CSL Behring $129.72 10/27/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678020
Principal investigator 1 CSL Behring $248.63 10/17/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678016
Principal investigator 5 CSL Behring $671,512.00 10/17/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252679044
Principal investigator 1 CSL Behring $150.00 10/15/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678885
Principal investigator 1 CSL Behring $845.00 10/15/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678887
Principal investigator 1 CSL Behring $272.00 10/15/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252679028
Principal investigator 1 GENZYME CORPORATION $2,948.00 10/14/2025 Non-covered Recipient Entity
Total Renal Research Inc Davita Clinical Research
ACT - POC clinical study - CD40L mAb - frexalimab No dispute reported 06/30/2026 1226083894
Principal investigator 1 Travere Therapeutics, Inc. $706.00 10/09/2025 Non-covered Recipient Entity
Medresearch Inc
DUPLEX study in FSGS No dispute reported 06/30/2026 1244186231
Principal investigator 1 Calliditas Therapeutics US Inc. $1,412.19 10/07/2025 Non-covered Recipient Entity
MEDRESEARCH INC
Nef-403 No dispute reported 06/30/2026 1235023490
Principal investigator 1 Calliditas Therapeutics US Inc. $1,150.02 10/07/2025 Non-covered Recipient Entity
MEDRESEARCH INC
Nef-403 No dispute reported 06/30/2026 1235023498
Principal investigator 1 CSL Behring $169.00 10/06/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252679152
Principal investigator 1 CSL Behring $204.00 10/06/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252679192
Principal investigator 1 CSL Behring $204.00 10/06/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252679194
Principal investigator 1 CSL Behring $272.00 10/06/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252679196
Principal investigator 1 GENZYME CORPORATION $3,499.00 10/06/2025 Non-covered Recipient Entity
Total Renal Research Inc Davita Clinical Research
ACT - POC clinical study - CD40L mAb - frexalimab No dispute reported 06/30/2026 1226083881
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841377
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841379
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841381
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841383
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841385
Principal investigator 1 AKEBIA THERAPEUTICS INC $801.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841387
Principal investigator 1 AKEBIA THERAPEUTICS INC $764.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841389
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841391
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841393
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841395
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841405
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841863
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841865
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841867
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841869
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841871
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841873
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842451
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842453
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842537
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842539
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842554
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842556
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842578
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842588
Principal investigator 1 AKEBIA THERAPEUTICS INC $265.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842590
Principal investigator 1 AKEBIA THERAPEUTICS INC $213.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842592
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842634
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842636
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842652
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842654
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842662
Principal investigator 1 AKEBIA THERAPEUTICS INC $265.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842702
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842732
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842738
Principal investigator 1 AKEBIA THERAPEUTICS INC $222.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843366
Principal investigator 1 AKEBIA THERAPEUTICS INC $53.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843368
Principal investigator 1 AKEBIA THERAPEUTICS INC $30.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843370
Principal investigator 1 AKEBIA THERAPEUTICS INC $126.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843372
Principal investigator 1 AKEBIA THERAPEUTICS INC $410.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241845222
Principal investigator 1 AKEBIA THERAPEUTICS INC $100.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241845283
Principal investigator 1 AKEBIA THERAPEUTICS INC $360.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241845336
Principal investigator 1 AKEBIA THERAPEUTICS INC $85.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241845340
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $500.00 10/02/2025 Non-covered Recipient Entity
Medresearch Inc
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225413909
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,000.00 10/02/2025 Non-covered Recipient Entity
EL PASO KIDNEY SPECIALISTS
A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular Diseases No dispute reported 06/30/2026 1190314027
Principal investigator 1 GENZYME CORPORATION $1,456.00 09/29/2025 Non-covered Recipient Entity
Total Renal Research Inc Davita Clinical Research
ACT - POC clinical study - CD40L mAb - frexalimab No dispute reported 06/30/2026 1226083877
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,416.22 09/25/2025 Non-covered Recipient Entity
Medresearch Inc
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225414718
Principal investigator 5 CSL Behring $495,933.00 09/18/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252679230
Principal investigator 1 CSL Behring $16,215.00 09/17/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252679084
Principal investigator 1 AKEBIA THERAPEUTICS INC $53.00 09/10/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843510
Principal investigator 1 AKEBIA THERAPEUTICS INC $222.00 09/10/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843512
Principal investigator 1 AKEBIA THERAPEUTICS INC $30.00 09/10/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843514
Principal investigator 1 AKEBIA THERAPEUTICS INC $126.00 09/10/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843516
Principal investigator 1 AKEBIA THERAPEUTICS INC $82.00 09/10/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241845129
Principal investigator 1 AKEBIA THERAPEUTICS INC $20.00 09/10/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241845191
Principal investigator 1 GENZYME CORPORATION $2,714.00 08/25/2025 Non-covered Recipient Entity
Total Renal Research Inc Davita Clinical Research
ACT - POC clinical study - CD40L mAb - frexalimab No dispute reported 06/30/2026 1226083861
Principal investigator 1 GENZYME CORPORATION $2,871.00 08/25/2025 Non-covered Recipient Entity
Total Renal Research Inc Davita Clinical Research
ACT - POC clinical study - CD40L mAb - frexalimab No dispute reported 06/30/2026 1226083870
Principal investigator 1 CSL Behring $25,064.00 08/20/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673632
Principal investigator 1 Alexion Pharmaceuticals, Inc. $2,015.76 08/19/2025 Non-covered Recipient Entity
MEDRESEARCH INC
A Phase 2, Double Blind, Randomized, Placebo Controlled Study of Ravulizumab in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) No dispute reported 06/30/2026 1185549013
Principal investigator 1 Calliditas Therapeutics US Inc. $250.00 08/19/2025 Non-covered Recipient Entity
MEDRESEARCH INC
Nef-403 No dispute reported 06/30/2026 1235023474
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $100.00 08/18/2025 Non-covered Recipient Entity
Medresearch Inc
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225413801
Principal investigator 5 CSL Behring $696,840.00 08/18/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673784
Principal investigator 1 CSL Behring $204.00 08/11/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673734
Principal investigator 1 CSL Behring $204.00 08/11/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673736
Principal investigator 1 GENZYME CORPORATION $8,637.00 08/11/2025 Non-covered Recipient Entity
Total Renal Research Inc Davita Clinical Research
ACT - POC clinical study - CD40L mAb - frexalimab No dispute reported 06/30/2026 1226083849
Principal investigator 1 AKEBIA THERAPEUTICS INC $53.00 08/06/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843681
Principal investigator 1 AKEBIA THERAPEUTICS INC $222.00 08/06/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843685
Principal investigator 1 AKEBIA THERAPEUTICS INC $30.00 08/06/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843688
Principal investigator 1 AKEBIA THERAPEUTICS INC $126.00 08/06/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843692
Principal investigator 1 AKEBIA THERAPEUTICS INC $53.00 08/06/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843942
Principal investigator 1 AKEBIA THERAPEUTICS INC $222.00 08/06/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843946
Principal investigator 1 AKEBIA THERAPEUTICS INC $30.00 08/06/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843949
Principal investigator 1 AKEBIA THERAPEUTICS INC $126.00 08/06/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843952
Principal investigator 1 AKEBIA THERAPEUTICS INC $410.00 08/06/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844933
Principal investigator 1 AKEBIA THERAPEUTICS INC $100.00 08/06/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844963
Principal investigator 1 AKEBIA THERAPEUTICS INC $369.00 08/06/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241845038
Principal investigator 1 AKEBIA THERAPEUTICS INC $90.00 08/06/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241845095
Principal investigator 1 CSL Behring $16.71 08/06/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678202
Principal investigator 1 GENZYME CORPORATION $3,506.00 07/28/2025 Non-covered Recipient Entity
Total Renal Research Inc Davita Clinical Research
ACT - POC clinical study - CD40L mAb - frexalimab No dispute reported 06/30/2026 1226083825
Principal investigator 1 GENZYME CORPORATION $3,556.00 07/28/2025 Non-covered Recipient Entity
Total Renal Research Inc Davita Clinical Research
ACT - POC clinical study - CD40L mAb - frexalimab No dispute reported 06/30/2026 1226083830
Principal investigator 1 CSL Behring $7,916.00 07/25/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673970
Principal investigator 1 AKEBIA THERAPEUTICS INC $53.00 07/23/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844517
Principal investigator 1 AKEBIA THERAPEUTICS INC $222.00 07/23/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844521
Principal investigator 1 AKEBIA THERAPEUTICS INC $30.00 07/23/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844526
Principal investigator 1 AKEBIA THERAPEUTICS INC $126.00 07/23/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844529
Principal investigator 1 AKEBIA THERAPEUTICS INC $53.00 07/23/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844758
Principal investigator 1 AKEBIA THERAPEUTICS INC $222.00 07/23/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844761
Principal investigator 1 AKEBIA THERAPEUTICS INC $30.00 07/23/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844764
Principal investigator 1 AKEBIA THERAPEUTICS INC $126.00 07/23/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844768
Principal investigator 1 AKEBIA THERAPEUTICS INC $600.00 07/23/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844837
Principal investigator 1 AKEBIA THERAPEUTICS INC $759.00 07/23/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844841
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,362.00 07/23/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844844
Principal investigator 1 AKEBIA THERAPEUTICS INC $912.00 07/23/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844848
Principal investigator 1 AKEBIA THERAPEUTICS INC $3,480.00 07/23/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844851
Principal investigator 1 AKEBIA THERAPEUTICS INC $360.00 07/23/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844855
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,767.00 07/23/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844858
Principal investigator 1 AKEBIA THERAPEUTICS INC $205.00 07/23/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844893
Principal investigator 1 AKEBIA THERAPEUTICS INC $50.00 07/23/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844919
Principal investigator 1 Calliditas Therapeutics US Inc. $5,774.52 07/21/2025 Non-covered Recipient Entity
MEDRESEARCH INC
Nef-403 No dispute reported 06/30/2026 1235023458
Principal investigator 1 Calliditas Therapeutics US Inc. $50.01 07/21/2025 Non-covered Recipient Entity
MEDRESEARCH INC
Nef-403 No dispute reported 06/30/2026 1235023462
Principal investigator 1 Travere Therapeutics, Inc. $1,146.60 07/18/2025 Non-covered Recipient Entity
Medresearch Inc
DUPLEX study in FSGS No dispute reported 06/30/2026 1244183996
Principal investigator 1 CSL Behring $69,813.00 07/16/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673904
Principal investigator 1 CSL Behring $408.00 07/09/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673882
Principal investigator 1 CSL Behring $204.00 07/09/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673966
Principal investigator 1 CSL Behring $402.00 07/07/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673960
Principal investigator 1 GENZYME CORPORATION $4,753.00 07/02/2025 Non-covered Recipient Entity
Total Renal Research Inc Davita Clinical Research
ACT - POC clinical study - CD40L mAb - frexalimab No dispute reported 06/30/2026 1226083804
Principal investigator 1 GENZYME CORPORATION $1,780.00 07/02/2025 Non-covered Recipient Entity
Total Renal Research Inc Davita Clinical Research
ACT - POC clinical study - CD40L mAb - frexalimab No dispute reported 06/30/2026 1226083808
Principal investigator 1 GENZYME CORPORATION $3,487.00 07/02/2025 Non-covered Recipient Entity
Total Renal Research Inc Davita Clinical Research
ACT - POC clinical study - CD40L mAb - frexalimab No dispute reported 06/30/2026 1226083812
Principal investigator 1 Calliditas Therapeutics US Inc. $4,362.33 06/17/2025 Non-covered Recipient Entity
MEDRESEARCH INC
Nef-403 No dispute reported 06/30/2026 1235023446
Principal investigator 1 Calliditas Therapeutics US Inc. $50.01 06/17/2025 Non-covered Recipient Entity
MEDRESEARCH INC
Nef-403 No dispute reported 06/30/2026 1235023448
Principal investigator 1 SANOFI US SERVICES INC. $2,800.00 06/16/2025 Non-covered Recipient Entity
Total Renal Research Inc Davita Clinical Research
ACT - POC clinical study - CD40L mAb - frexalimab No dispute reported 06/30/2026 1226083781
Principal investigator 1 SANOFI US SERVICES INC. $3,711.00 06/16/2025 Non-covered Recipient Entity
Total Renal Research Inc Davita Clinical Research
ACT - POC clinical study - CD40L mAb - frexalimab No dispute reported 06/30/2026 1226083786
Principal investigator 1 Calliditas Therapeutics US Inc. $50.01 06/04/2025 Non-covered Recipient Entity
MEDRESEARCH INC
Nef-403 No dispute reported 06/30/2026 1235023436
Principal investigator 1 CSL Behring $518.90 06/03/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678090
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,223.95 05/30/2025 Non-covered Recipient Entity
Medresearch Inc
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225412824
Principal investigator 1 Travere Therapeutics, Inc. $1,187.00 05/21/2025 Non-covered Recipient Entity
Medresearch Inc
DUPLEX study in FSGS No dispute reported 06/30/2026 1244185934
Principal investigator 1 Travere Therapeutics, Inc. $949.60 05/21/2025 Non-covered Recipient Entity
Medresearch Inc
DUPLEX study in FSGS No dispute reported 06/30/2026 1244185938
Principal investigator 1 GENZYME CORPORATION $6,017.00 05/19/2025 Non-covered Recipient Entity
Total Renal Research Inc Davita Clinical Research
ACT - POC clinical study - CD40L mAb - frexalimab No dispute reported 06/30/2026 1226083793
Principal investigator 1 Travere Therapeutics, Inc. $103.00 05/16/2025 Non-covered Recipient Entity
Medresearch Inc
DUPLEX study in FSGS No dispute reported 06/30/2026 1244186883
Principal investigator 1 CSL Behring $5,544.00 05/14/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673816
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,722.82 05/12/2025 Non-covered Recipient Entity
EL PASO KIDNEY SPECIALISTS
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function No dispute reported 06/30/2026 1190312919
Principal investigator 1 CSL Behring $1,362.03 05/08/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678078
Principal investigator 1 GENZYME CORPORATION $5,115.00 05/05/2025 Non-covered Recipient Entity
Total Renal Research Inc Davita Clinical Research
ACT - POC clinical study - CD40L mAb - frexalimab No dispute reported 06/30/2026 1226083761
Principal investigator 1 CSL Behring $1,977.00 04/16/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673938
Principal investigator 1 Calliditas Therapeutics US Inc. $50.01 04/10/2025 Non-covered Recipient Entity
MEDRESEARCH INC
Nef-403 No dispute reported 06/30/2026 1235023426
Principal investigator 1 CSL Behring $16.71 04/09/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678120
Principal investigator 1 CSL Behring $3,624.39 04/09/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678434
Principal investigator 1 GENZYME CORPORATION $4,753.00 04/07/2025 Non-covered Recipient Entity
Total Renal Research Inc Davita Clinical Research
ACT - POC clinical study - CD40L mAb - frexalimab No dispute reported 06/30/2026 1226083740
Principal investigator 1 GENZYME CORPORATION $17,218.00 04/02/2025 Non-covered Recipient Entity
Total Renal Research Inc Davita Clinical Research
ACT - POC clinical study - CD40L mAb - frexalimab No dispute reported 06/30/2026 1226083736
Principal investigator 1 CSL Behring $605.38 03/31/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678396
Principal investigator 1 CSL Behring $7,521.00 03/19/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252674124
Principal investigator 1 Calliditas Therapeutics US Inc. $50.01 03/10/2025 Non-covered Recipient Entity
MEDRESEARCH INC
Nef-403 No dispute reported 06/30/2026 1235023416
Principal investigator 1 Alnylam Pharmaceuticals Inc. $37,499.00 02/21/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522372
Principal investigator 1 CSL Behring $786.40 02/21/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678366
Principal investigator 1 CSL Behring $12,477.00 02/19/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252674096
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,000.00 02/07/2025 Non-covered Recipient Entity
Total Renal Research Inc
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1225405122
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,206.61 01/28/2025 Non-covered Recipient Entity
Medresearch Inc
BAY 948862, A randomised, double-blind, placebo-controlled, parallel-group, multicentre Phase 3 study to investigate the efficacy and safety of Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic No dispute reported 06/30/2026 1225404008
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $73,991.32 01/27/2025 Non-covered Recipient Entity
DAVITA CLINICAL RESEARCH EL PASO
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Povetacicept in Adults With Immunoglobulin A Nephropathy (RAINIER) No dispute reported 06/30/2026 1214124096
Principal investigator 1 CSL Behring $594.61 01/22/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678316
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,445.27 01/22/2025 Non-covered Recipient Entity
EL PASO KIDNEY SPECIALISTS
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function No dispute reported 06/30/2026 1190312921
Principal investigator 1 Calliditas Therapeutics US Inc. $250.00 01/21/2025 Non-covered Recipient Entity
MEDRESEARCH INC
Nef-403 No dispute reported 06/30/2026 1235023412
Principal investigator 1 Travere Therapeutics, Inc. $2,400.00 01/21/2025 Non-covered Recipient Entity
Medresearch Inc
DUPLEX study in FSGS No dispute reported 06/30/2026 1244183883
Principal investigator 1 AstraZeneca UK Limited $52,515.00 01/13/2025 Non-covered Recipient Entity
TOTAL RENAL RESEARCH
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 1185549015
Principal investigator 1 CSL Behring $5,279.00 01/10/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252674044
Principal investigator 1 CSL Behring $8,405.00 01/10/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252674046
Principal investigator 1 Travere Therapeutics, Inc. $40.00 01/10/2025 Non-covered Recipient Entity
Medresearch Inc
DUPLEX study in FSGS No dispute reported 06/30/2026 1244183880